Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia.

MLA

Furman, Richard R., et al. “Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia.” New England Journal of Medicine, vol. 370, no. 11, Mar. 2014, pp. 997–1007. EBSCOhost, https://doi.org/10.1056/NEJMoa1315226.

APA

Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., Ghia, P., Eradat, H., Ervin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., Path, F. R. C., Shuo Ma, Stilgenbauer, S., & Cramer, P. (2014). Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 370(11), 997–1007. https://doi.org/10.1056/NEJMoa1315226

Chicago

Furman, Richard R., Jeff P. Sharman, Steven E. Coutre, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, et al. 2014. “Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia.” New England Journal of Medicine 370 (11): 997–1007. doi:10.1056/NEJMoa1315226.